234 results about "Lower blood pressure" patented technology

The invention relates to the field of blood pressure measurement, and discloses a blood pressure measurement method and system, electronic equipment and a medium. According to the blood pressure measuring method, in the pressure boosting stage of blood pressure measurement, the real-time air pressure value of the air channel communicated with the air bag is detected, and then the air valve driving circuit is controlled according to the real-time air pressure value, for example, when the air pressure of the air bag is low, the air valve can be driven to work through small driving voltage, and when the air pressure of the air bag is high, the air valve driving circuit is controlled. Large driving voltage is adopted to drive the air valve to work. Thus, the driving voltage of the air valve is dynamically adjusted in the boosting process, compared with the mode that the air valve is driven to work by adopting fixed high driving voltage, the air valve can complete work with low power consumption under the condition that the requirement for the air leakage amount is met, and therefore the blood pressure measuring efficiency is improved by optimizing the power consumption consumed in the blood pressure measuring process every time. The overall power consumption of the blood pressure measuring system can be reduced, so that the cruising ability of the wearable device is improved, and the target of long-term blood pressure monitoring is finally achieved.

To provide a system for transmitting blood pressure reduction electrical stimulation to the heart of a patient capable of determining a desirable AV delay.SOLUTION: The atrium is paced and the ventricle is paced with a given (arbitrary) delay to obtain a desired blood pressure change. Then, the atrium is sensed, the ventricle is paced, the blood pressure change is observed, and the resulting blood pressure change is compared with the paced-atrium-paced-ventricle desired blood pressure change. In the case where the blood pressure changes are not substantially equal, the timing of the sensed-atrium-paced-ventricle stimulation is adjusted on the basis of the comparison. The new modified resulting blood pressure change is observed, and the modified blood pressure change is compared with the paced-atrium-paced-ventricle desired blood pressure change. Adjustment and observation may be repeated until the timing of the sensed-atrium-paced-ventricle stimulation achieves the same blood pressure change as the desired blood pressure change of the paced-atrium-paced-ventricle stimulation.SELECTED DRAWING: Figure 9

The invention discloses an ACE (Angiotensin Converting Enzyme) inhibition and DPP-IV (Dipeptidyl Peptidase-IV) inhibition bifunctional peptide as well as a design method and application thereof. The amino acid sequence of the bifunctional peptide fragment is Trp-Ala-Leu-Val-Ala-Pro or Trp-Pro-Leu-Val-Ala-Pro. According to the design method, hydrophobic amino acid replacement is carried out on most N-terminal first amino acid according to the characteristics of the DPP-IV inhibitory peptide, and N-terminal second amino acid is kept as proline Pro or alanine Ala. The difunctional peptide fragment obtained through the DPP-IV inhibitory activity optimization strategy has the effects of assisting in lowering blood pressure and lowering blood sugar at the same time and can be used for preparing functional food or health food with the functions of assisting in lowering blood pressure and lowering blood sugar, and the optimization strategy can be applied to improving the blood sugar lowering effect of the peptide fragment and has good market application prospects.

The invention discloses preparation and application of lotus seed protein peptide with ACE (angiotensin converting enzyme) inhibitory activity, and belongs to the technical field of food-borne active peptide development. According to the ACE inhibitory peptide WVPRYFPF and the preparation method thereof, the ACE inhibitory peptide is rapidly screened by utilizing a polypeptiomics and molecular docking technology, the defects of time consumption and labor consumption caused by step-by-step separation and purification are avoided, the obtained ACE inhibitory peptide WVPRYFPF has extremely high ACE inhibitory activity, IC50 of the ACE inhibitory peptide WVPRYFPF is 16.7 mu M, and the ACE inhibitory peptide WVPRYFPF can be used for assisting or replacing hypertension drugs. The lotus seed protein peptide disclosed by the invention has the characteristic of inhibiting ACE enzyme activity in vitro, and animal experiments prove that the protein peptide can also play a role in lowering blood pressure in a spontaneous hypertension rat (SHR).

The invention provides a hemodialysis hypotension prediction system based on machine learning, which relates to the technical field of medical health, and comprises a real-time data stream processing module, a dynamic modeling and prediction module, a real-time data stream processing module, a real-time data stream processing module, a real-time data stream processing module, a real-time data stream processing module and a real-time data stream processing module, the risk prediction module is used for dynamically modeling and predicting the hypotension risk of a patient according to physiological parameter data input in real time, and the personalized adaptation module is used for automatically adjusting a risk prediction model. According to the hemodialysis hypotension prediction system based on machine learning, by introducing the real-time data flow processing module, physiological parameter data in the hemodialysis process can be collected and processed in real time. By adopting the dynamic modeling and predicting module, the hypotension risk can be dynamically modeled and predicted based on the physiological parameter data input in real time, and the prediction model is automatically adjusted through the personalized adaptation module, so that the risk prediction result of each patient is more accurate.

The invention relates to a blood pressure compensation measurement method and device for a motion scene and a smart watch, and the method comprises the steps: generating a lactic acid accumulation mark through fusing a motion acceleration signal and a heart rate signal, extracting a specific frequency band component of a pressure shock wave signal based on the mark, and generating a time domain envelope line; quantifying envelope line main peak width change and frequency domain energy distribution abnormity to generate tension abnormity, and mapping the tension abnormity into a blood vessel volume dynamic change curve; constructing a biomechanical compensation curve in combination with a static blood vessel volume reference, and reconstructing an envelope line for eliminating blood vessel tension interference through frequency domain convolution; and finally, positioning a blood pressure feature point based on the reconstructed envelope differential feature and outputting a compensated blood pressure value. According to the method, a lactic acid metabolism and vascular biomechanical characteristic compensation model is established for the first time, the problem of systematic offset of feature points caused by abnormal vascular tension after movement is solved, and the blood pressure measurement error is remarkably reduced.

The invention discloses a method for establishing a hypoperfusion cerebral infarction model, which is used for simulating a clinical cerebral infarction animal model caused by low blood pressure by adopting a method for establishing a model for combining hypotension with improved middle cerebral artery occlusion (MCAO) rats. Compared with the prior art, the technical method that existing bilateral carotid artery ligation can only simulate chronic cerebral ischemia, ischemic infarction lesions are not formed, and hypoperfusion cerebral infarction cannot be simulated is broken through, the composite method that blood pressure reduction is combined with MCAO improvement is used for the first time, and the clinical common pathological state of cerebral blood flow hypoperfusion cerebral infarction caused by hypotension is simulated. According to the invention, the pathologic process of occurrence and development of the disease and the pharmacology of the drug are researched, and the drug action mechanism is explained; a reliable animal model is provided for new drug research and development.

The invention relates to the technical field of data processing, and discloses a method and system for predicting a hypotension risk in dialysis based on machine learning. The method comprises the following steps: calculating an ultrafiltration rate-blood pressure decreasing amplitude coupling coefficient by collecting ultrafiltration rate, blood flow volume, transmembrane pressure and blood pressure data in a dialysis process, obtaining a dialysis tolerance index in combination with a vascular compliance parameter, and constructing a stage weighting function according to dialysis duration to determine a weight coefficient of each period; and performing weighted calculation with individual baseline dialysis tolerance to set a personalized risk threshold value, and establishing a sliding window prediction mechanism to predict the probability of occurrence of hypotension in the future. The problems that a static prediction mode cannot adapt to dynamic changes in the dialysis process and is lack of personalized risk assessment are solved, and the accuracy and timeliness of hypotension risk prediction in dialysis are improved.

The invention discloses ACE (Angiotensin Converting Enzyme) inhibitory decapeptide IR10 derived from bovine cheese protein hydrolysate and application of the ACE inhibitory decapeptide IR10, and relates to the technical field of bioactive peptides, and the technical scheme of the ACE inhibitory decapeptide IR10 is characterized in that the amino acid sequence is IQKEDVPSER. The ACE inhibitory decapeptide IR10 derived from the cattle cheese protein hydrolysate is obtained by screening from the cattle cheese protein hydrolysate and is decapeptide IR10 with ACE inhibitory activity, the in-vitro ACE inhibition rate of the ACE inhibitory decapeptide IR10 derived from the cattle cheese protein hydrolysate is tested to be 62.07% under the condition of the concentration of 1mg / ml, and the ACE inhibitory decapeptide IR10 has the effect of being suitable for functional food for assisting blood pressure reduction.

The invention discloses a composition for reducing blood pressure, blood sugar and blood fat, and belongs to the technical field of food processing. The moringa oleifera health-care food is prepared from moringa oleifera leaf powder, mulberry leaf powder, wall-broken ganoderma lucidum spore powder, passion fruit powder, prune powder, sea buckthorn powder, roxburgh rose powder, acerola cherry powder, angelica keiskei powder, corn stigma extract, perfume lemon powder, cyclocarya paliurus extract, radix puerariae extract, globe artichoke extract, lecithin, enzymes, OMEGA-3, arabinose and fructo-oligosaccharide. The plant composition which is sour with sweetness and good in taste is prepared by compounding and seasoning all edible raw materials such as glucosyl stevioside / hesperidin, the plant composition has good effects of reducing blood pressure, blood sugar and blood fat, and the adopted raw materials are healthy, non-toxic, easy to obtain, non-toxic to human bodies, especially livers, suitable for popular use and good in application prospect.

The invention provides a theaflavin composition for treating hypertension as well as a preparation method and application thereof, and relates to the technical field of medicines. The theaflavin composition comprises theaflavin, a celery seed extract, a gastrodia elata extract, a parasitic loranthus extract, a centella asiatica extract, a lotus leaf extract and a licorice extract. Wherein the theaflavin can regulate blood fat, inhibit atherosclerosis and improve the vascular endothelial function; the celery seed extract inhibits the activity of angiotensin converting enzyme, and cooperates with theaflavin to regulate blood pressure; the gastrodia elata extract can calm liver wind and improve cerebral circulation; the loranthus parasiticus extract has the effects of tonifying liver and kidney and regulating water sodium metabolism; the centella asiatica extract can resist inflammation and repair vascular endothelium; the lotus leaf extract can clear heat, promote diuresis, calm the liver and suppress yang; and the licorice extract harmonizes the medicines and resists oxidation. According to the invention, theaflavin is taken as a core, multi-dimensional effects of reducing blood pressure, protecting blood vessels and resisting inflammation and oxidation are realized, and a natural and comprehensive health management scheme is provided for hypertensive patients.

The invention belongs to the technical field of medicines, and mainly relates to application of 3 ', 4'-dihydroxy flavonol in treatment of hypertension. The invention firstly provides application of 3 ', 4'-dihydroxy flavonol or pharmaceutically acceptable salt thereof in preparation of products for preventing and / or treating hypertension. The invention also provides an application of the 3 ', 4'-dihydroxy flavonol or the pharmaceutically acceptable salt thereof in preparation of a product, and the product is used for reducing blood pressure; the blood vessel function reduction is improved; the blood vessel wall thickening is improved; the heart function reduction is improved; the 3 ', 4'-dihydroxy flavonol can improve any one or more of myocardial cell hypertrophy, and the invention further provides a product which comprises an effective dose of 3 ', 4'-dihydroxy flavonol or pharmaceutically acceptable salt thereof. The application finds that the 3 ', 4'-dihydroxy flavonol and the pharmaceutically acceptable salt thereof can be effectively used for preventing or treating hypertension, and a new way is opened up for the treatment of hypertension or hypertension-related diseases.

The invention discloses a bifunctional active peptide with ACE (angiotensin converting enzyme) and DPP-IV (dipeptidyl peptidase-IV) inhibitory activity as well as a preparation method and application of the bifunctional active peptide, and belongs to the technical field of active peptide biology. The difunctional novel active peptide with ACE and DPP-IV inhibitory activity is prepared and identified from sea cucumber enzymatic hydrolysate, not only can inhibit ACE activity, but also has DPP-IV inhibitory activity, and the difunctional novel active peptide has application value in preparation of products with blood pressure and blood sugar reducing effects. The active peptide provided by the invention can significantly inhibit the activity of ACE, has DPP-IV inhibitory activity, has the characteristics of simple structure, safety, strong activity and the like, can exert nutritional and health-care effects, is expected to provide effective active ingredients for developing food and products having no side effects and having the effects of reducing blood pressure and blood sugar or having the effects of reducing blood pressure and blood sugar and the like, and has a broad application prospect. Wide application prospects are realized.

The invention provides an angiotensin converting enzyme inhibitory peptide and application thereof. The amino acid sequence of the angiotensin converting enzyme inhibitory peptide is PVKP. The ACE inhibitory activity of the inhibitory peptide PVKP provided by the invention is obviously improved compared with that of the original inhibitory peptide LYPVK, and the IC50 value is reduced from 10.6 mu g / mL to 9.6 mu g / mL; the digestive enzyme stability of the inhibitory peptide PVKP provided by the invention and the digestive enzyme stability of the original inhibitory peptide LYPVK under the same concentration are improved. Molecular simulation docking verifies that the interaction force between the ACE inhibitory peptide PVKP and ACE is enhanced compared with that of an original inhibitory peptide LYPVK, and the interaction force between alkyl groups and the interaction between the alkyl groups and Zn < 2 + > of an ACE active center are increased. The intracellular antihypertensive activity of the ACE inhibitory peptide PVKP is further verified through cell experiments, and compared with the original inhibitory peptide LYPVK, the intracellular NO release content is increased, and the ET-1 content is reduced. The ACE inhibitory peptide PVKP is small in molecular weight and good in water solubility, and application of the ACE inhibitory peptide PVKP in development of products with the blood pressure lowering effect is facilitated.

Methods and devices for reducing ventricle filling volume are disclosed. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to reduce ventricle filling volume or even blood pressure. When the heart is stimulated in a consistent way to reduce blood pressure, the cardiovascular system may over time adapt to the stimulation and revert back to the higher blood pressure. In some embodiments, the stimulation pattern may be configured to be inconsistent such that the adaptation response of the heart is reduced or even prevented. In some embodiments, an electrical stimulator may be used to stimulate a patient's heart to cause at least a portion of an atrial contraction to occur while the atrioventricular valve is closed. Such an atrial contraction may deposit less blood into the corresponding ventricle than when the atrioventricular valve is opened throughout an atrial contraction.

The invention discloses a goat milk bioactive polypeptide with antioxidation and angiotensin converting enzyme inhibition activity, and preparation and application thereof, and belongs to the field of biological polypeptides, and a preparation method and application thereof. In-vitro tests prove that the polypeptide has an excellent antioxidant effect, can remarkably reduce blood pressure and is beneficial to prevention and treatment of cardiovascular diseases, the interaction mechanism of the polypeptide and ACE is defined by using a molecular docking technology, scientific basis and targets are provided for research and development of new drugs, and the polypeptide has potential physiological functions such as antioxidant activity and ACE inhibitory activity and has a broad application prospect. The method is suitable for functional food and medicine development and has a wide application prospect.

The invention discloses application of melastoma dodecandrum lour in preparation of antihypertensive drugs and drugs for treating hypertension complications. It is found for the first time that by means of melastoma dodecandrum extract treatment, AKT1 and EGFR protein expression related to hypertension can be lowered, blood pressure (Plt, 0.05) and cardiac fibrosis degree (Plt, 0.01) of spontaneously hypertensive rats (SHR) can be remarkably lowered, inflammatory response (Plt, 0.05) can be inhibited, and the effect of treating the melastoma dodecandrum extract can be achieved. The melastoma dodecandrum not only has the effect of reducing blood pressure, but also has the functions of improving myocardial fibrosis and inhibiting inflammatory response; moreover, the melastoma dodecandrum lour has no toxic or side effect on the body, is safe and reliable to use, shows that the melastoma dodecandrum lour has good research and development prospects of reducing blood pressure, improving myocardial fibrosis and resisting ventricular remodeling, and provides a new effective way for hypertension and corresponding complications.

The invention discloses a polypeptide with antihypertensive and hypoglycemic effects and a preparation method and application thereof. The invention discloses a polypeptide with effects of reducing blood pressure and reducing blood sugar. The amino acid sequence of the polypeptide is shown as SEQ ID NO.1, or SEQ ID NO.3, or SEQ ID NO.4, or SEQ ID NO.5, or SEQ ID NO.6, or SEQ ID NO.8, or SEQ ID NO.9, or SEQ ID NO.10. The invention further discloses a preparation method of the polypeptide. The application of the polypeptide is used for manufacturing medicines with the functions of reducing blood pressure and blood sugar. The invention also discloses a preparation method of the polypeptide with the effects of reducing blood pressure and blood sugar. The polypeptide provided by the invention not only can effectively inhibit ACE activity and reduce blood pressure, but also can regulate the blood sugar level by inhibiting DPP4 activity, and the preparation method is simple, the production cost is low, and the biological activity is high.

The invention relates to the field of biological medicine, in particular to a decarboxylated carnosine composite liposome and application thereof in preparation of products for reducing uric acid and dissolving tophus. The decarboxylated carnosine composite liposome is formed by self-assembling raw materials including decarboxylated carnosine, alkaloid, flavone, a polygonum cuspidatum extract, p-coumaric acid, a liquorice extract, a semen coicis extract, a yam rhizome extract, a poria cocos extract and quercetin, and research proves that the decarboxylated carnosine composite liposome can reduce uric acid, dissolve ventilation stone and balance in-vivo acid-base balance; the composition inhibits xanthine oxidase from synthesizing uric acid, promotes uric acid excretion and intestinal tract movement in the body, repairs damaged liver and kidney cells, diminishes swelling, resists inflammation, relieves pain, prevents and treats hyperuricemia, relieves gout inflammation, reduces blood pressure and improves immunity.

The embodiment of the invention discloses a blood pressure detection method and device which are applied to electronic equipment. The method comprises the following steps: acquiring a first photoplethysmography (PPG) signal of a user, and determining a first electrocardio (ECG) signal of the user based on the first PPG signal; performing peak detection on the first PPG signal and the first ECG to determine first pulse transit time of the user; and performing first quality detection on the first ECG signal and the first pulse conduction time, and if it is determined that the result of the first quality detection is normal, determining the blood pressure value of the user based on the first pulse conduction time. By adopting the embodiment of the invention, the accuracy of a blood pressure detection result can be improved, and the blood pressure detection cost is reduced.

The invention belongs to the technical field of biological medicines, and particularly relates to a preparation method and application of a plant extract. The tartary buckwheat active polypeptide is prepared by performing enzymolysis reaction on tartary buckwheat protein. The tartary buckwheat active polypeptide can effectively inhibit the activity of angiotensin converting enzyme (ACE), so that the tartary buckwheat active polypeptide can be used as an ACE inhibitor to reduce blood pressure. The plant extract disclosed by the invention not only has the functions of high-efficiency antihypertensive effect, no toxicity, no side effect and the like, but also has the advantages of simplicity in preparation, easiness in absorption and the like, and avoids adverse effects of side effects of traditional chemical medicines on human bodies.

The invention discloses a dexmedetomidine and propofol combined reagent and a combination method, and relates to the technical field of combined use of anesthetic drugs. According to the method, firstly, dexmedetomidine is subjected to intravenous pump injection within 5-15 minutes according to the dosage of 0.5-1.0 mu g / kg, propofol is given within 2 minutes after the dexmedetomidine is subjected to general anesthesia, and the dosage of the propofol can be reduced by 10%-50% compared with that of propofol which is independently used. Through pretreatment of dexmedetomidine, the anesthetic effect of propofol can be enhanced, adverse reactions such as blood pressure drop and respiratory depression can be effectively reduced, and anesthetic safety and controllability are improved. The combined reagent comprises independent containers for respectively loading the dexmedetomidine injection and the propofol emulsion, and can be packaged by adopting a double-cavity pre-filled injector, and sequential injection is realized through a controllable opening mechanism, so that unstable emulsification and titer change caused by physical mixing of medicines are avoided.

The invention discloses an application of Ackermann muciniphile and an outer membrane protein Amuc1100 of Ackermann muciniphile in treatment of hypertension. The outer membrane protein Amuc1100 is a protein of which the amino acid sequence is as shown in SEQ ID NO: 4. Experiments prove that the outer membrane protein Amuc1100 can enhance the intestinal barrier function of a mouse, blood pressure is reduced by remodeling the cardiovascular system and improving the intestinal microenvironment, and the blood pressure comprises systolic pressure and diastolic pressure. The invention has important application value in prevention and / or treatment of hypertension.

The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of plant polypeptide. The schisandra chinensis active polypeptide is prepared by carrying out enzymolysis reaction on schisandra chinensis protein. The schisandra chinensis active polypeptide can effectively inhibit the activity of angiotensin converting enzyme (ACE), so that the schisandra chinensis active polypeptide can be used as an ACE inhibitor to reduce blood pressure. The plant extract disclosed by the invention not only has the functions of high-efficiency antihypertensive effect, no toxicity, no side effect and the like, but also has the advantages of simplicity in preparation, easiness in absorption and the like, and avoids adverse effects of side effects of traditional chemical medicines on human bodies.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from aspirin, atorvastatin, valsartan, hydrochlorothiazide, folic acid substances and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition provided by the invention has the advantages that the pharmaceutical composition provided by the invention has a multi-target synergistic prevention effect on vascular diseases, especially cerebral embolism, that is, the composition not only can reduce blood pressure, blood fat and blood homocysteine level, but also has an effect of preventing thrombosis, and reduces the risk of cerebral apoplexy. In addition, the form of the pharmaceutical composition is beneficial to improving the medication compliance of patients.

The present invention belongs to the technical field of functional oligopeptides, and discloses a hydrolyzed casein oligopeptide with auxiliary blood pressure lowering function and its preparation method and application. The present invention uses casein as raw material, collects casein hydrolyzate containing active peptides through directional and controllable enzymolysis, and obtains the above-mentioned hydrolyzed casein oligopeptide with significant blood pressure lowering function. It also has the effect of lowering blood lipids, improving endothelial function and vascular elasticity. In the present invention, the main sequence of the hydrolyzed casein oligopeptide with blood pressure lowering function containing the hydrolyzed casein oligopeptide with blood pressure lowering function is VNEISK, LQSW, VLPVPQK, MIMKEP, GPFPIIV, FFVAPFPEVFGK, wherein VNEISK is the hydrolyzed casein oligopeptide with the auxiliary blood pressure lowering function newly discovered in this study with the largest activity and the highest content, which has the effect of assisting in lowering blood pressure, softening blood vessels, improving vascular elasticity, and improving headaches, dizziness, palpitations, tinnitus, insomnia and the like caused by hypertension. The blood pressure lowering peptide prepared by the present invention can be used in various forms of products such as milk powder, beverages, and tablet candies.

A plant lactobacillus JN9, a preparation, a probiotic composition and its use. The present application obtains a new plant lactobacillus JN9 through screening, and the deposit number is: CCTCC NO: M 20241647. Through the basic characteristic analysis (growth curve, acid resistance, bile salt resistance, gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolytic ability, toxin production ability, cytotoxicity, ability to produce bioamines), adhesion evaluation, GABA production evaluation, alcohol tolerance and acetaldehyde dehydrogenase production ability evaluation of the strain, it is found that it is a safe strain with excellent GABA production performance, high alcohol tolerance and high acetaldehyde dehydrogenase enzyme activity. It can be used to improve mood such as relieving stress, anti-depression and improving the body's sleep quality, lowering blood pressure, anti-diabetes, anti-cancer, anti-oxidation, anti-inflammatory, anti-microbial, anti-allergic, and enhancing alcohol tolerance during drinking and relieving discomfort after drinking.

This invention relates to a blood pressure compensation measurement method, device, and smartwatch for sports scenarios. The method generates a lactate accumulation marker by fusing motion acceleration and heart rate signals. Based on this marker, specific frequency components of the pressure oscillation wave signal are extracted and a time-domain envelope is generated. The variation in the width of the envelope's main peak and the abnormal frequency-domain energy distribution are quantified to generate a tension anomaly, which is then mapped to a dynamic vascular volume change curve. A biomechanical compensation curve is constructed using a static vascular volume benchmark, and the envelope, free from vascular tension interference, is reconstructed through frequency-domain convolution. Finally, blood pressure feature points are located based on the differential features of the reconstructed envelope, and a compensated blood pressure value is output. This method establishes, for the first time, a compensation model for lactate metabolism and vascular biomechanical characteristics, solving the problem of systematic shift of feature points caused by abnormal vascular tension after exercise, and significantly reducing blood pressure measurement errors.

The invention discloses an application of berberine in preparation of a medicine for treating hypertension. Experiments prove that berberine can improve changes of intestinal pathology caused by angiotensin II, blood pressure is reduced by adjusting intestinal flora, especially increasing abundance of Ackermann mucilaginophile and remodeling cardiovascular system, and blood pressure comprises systolic pressure and diastolic pressure. The invention has important application value in treatment of hypertension.

The invention discloses application of geum aleppicum total triterpenes in treatment of hypertension and a preparation method of the geum aleppicum total triterpenes, the geum aleppicum total triterpenes are obtained by step-by-step extraction and purification of geum aleppicum, and the geum aleppicum total triterpenes comprise bitter raspberry sweet F1, 2-hydroxyl oleanolic acid, 2-hydroxyl ursolic acid, 20beta, 20beta, 20beta, 20beta, 20beta, 20beta, 20beta, 20beta, 20beta The traditional Chinese medicine composition is prepared from the following raw materials in percentage by weight: 28-epoxy-28-hydroxytaxasan-3 beta-ol (taraxane triterpenes), ursolic acid, maslinic acid, rosa multiflora acid and tormentic acid. According to the present invention, the geum aleppicum total triterpenes are extracted and purified from the geum aleppicum step by step, and the geum aleppicum total triterpenes can significantly increase the total cross-sectional area of the vascular bed of the ischemic tissue or organ, such that the low blood pressure can meet the blood perfusion for maintaining the life activity so as to achieve the blood pressure lowering purpose; the compound can be widely applied to the field of hypertension prevention and treatment medicines.